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Abstract
Alpha-1 antitrypsin deficiency is a recently identified genetic disease that occurs almost as frequently as cystic fibrosis. It is caused by various 
mutations in the SERPINA1 gene, and has numerous clinical implications. Alpha-1 antitrypsin is mainly produced in the liver and acts as an 
antiprotease. Its principal function is to inactivate neutrophil elastase, preventing tissue damage. The mutation most commonly associated 
with the clinical disease is the Z allele, which causes polymerization and accumulation within hepatocytes. The accumulation of and the 
consequent reduction in the serum levels of alpha-1 antitrypsin cause, respectively, liver and lung disease, the latter occurring mainly as early 
emphysema, predominantly in the lung bases. Diagnosis involves detection of low serum levels of alpha-1 antitrypsin as well as phenotypic 
confirmation. In addition to the standard treatment of chronic obstructive pulmonary disease, specific therapy consisting of infusion of 
purified alpha-1 antitrypsin is currently available. The clinical efficacy of this therapy, which appears to be safe, has yet to be definitively 
established, and its cost-effectiveness is also a controversial issue that is rarely addressed. Despite its importance, in Brazil, there are no 
epidemiological data on the prevalence of the disease or the frequency of occurrence of deficiency alleles. Underdiagnosis has also been a 
significant limitation to the study of the disease as well as to appropriate treatment of patients. It is hoped that the creation of the Alpha 
One International Registry will resolve these and other important issues.
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Resumo
A deficiência de alfa-1 antitripsina é um distúrbio genético de descoberta recente e que ocorre com freqüência comparável à da fibrose cística. 
Resulta de diferentes mutações no gene SERPINA1 e tem diversas implicações clínicas. A alfa-1 antitripsina é produzida principalmente no 
fígado e atua como uma antiprotease. Tem como principal função inativar a elastase neutrofílica, impedindo a ocorrência de dano tecidual. 
A mutação mais freqüentemente relacionada à doença clínica é o alelo Z, que determina polimerização e acúmulo dentro dos hepatócitos. O 
acúmulo e a conseqüente redução dos níveis séricos de alfa-1 antitripsina determinam, respectivamente, doença hepática e pulmonar, sendo 
que esta se manifesta principalmente sob a forma de enfisema de aparecimento precoce, habitualmente com predomínio basal. O diagnós-
tico envolve a detecção de níveis séricos reduzidos de alfa-1 antitripsina e a confirmação fenotípica. Além do tratamento usual para doença 
pulmonar obstrutiva crônica, existe atualmente uma terapia específica com infusão de concentrados de alfa-1 antitripsina. Essa terapia de 
reposição, aparentemente segura, ainda não teve a eficácia clínica definitivamente comprovada, e o custo-efetividade também é um tema 
controverso e ainda pouco abordado. Apesar da sua importância, não existem dados epidemiológicos brasileiros a respeito da prevalência da 
doença ou da freqüência de ocorrência dos alelos deficientes. O subdiagnóstico também tem sido uma importante limitação tanto para o 
estudo da doença quanto para o tratamento adequado dos pacientes. Espera-se que a criação do Registro Internacional de Alfa-1 venha a 
resolver essas e outras importantes questões.
Descritores: alfa 1-antitripsina, Enfisema; Doença pulmonar obstrutiva crônica.
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Pulmonar (PLATINO, Latin-American Project for the 
Investigation of Pulmonary Obstruction), designed 
for tracking cases of chronic obstructive pulmonary 
disease (COPD) and conducted in the city of São 
Paulo, it was found that 15.8% of individuals aged 
40 or older had COPD, and that 12.5% of those 
 individuals had never been exposed to tobacco 
smoke.(9) Based on these data, we can infer that 
COPD risk factors other than smoking, among which 
is AAT deficiency, are important in Brazil. Another 
study demonstrated that 2-3% of individuals with 
COPD present severe AAT deficiency.(10) According to 
the PLATINO study, there are 5 to 7 million individ-
uals with COPD in Brazil. However, it is not known 
how many of those individuals have AAT deficiency 
or which is the most common deficiency allele. A 
study conducted in Brazil(11) found that 12.8% of 
the individuals studied were heterozygous for the 
S or Z allele or for the compound; however, the 
sample was not representative of the Brazilian 
population, since it included only individuals with 
cystic fibrosis.
Data from another study show that, in Spain, 
approximately 1.2 million (3%) of the 40 million 
inhabitants carry the Z allele, and that there 
are approximately 12,000 individuals who are 
homozygous for PiZZ and present concomitant severe 
AAT deficiency.(12) In the same study, the frequency of 
the main deficiency phenotypes was also estimated. 
The most prevalent would be PiMS (80%), followed 
by PiMZ (13%), PiSS (4.7%), PiSZ (1.6%), and PiZZ 
(0.1%). In addition, penetrance estimates indicated 
that there would be  approximately 2,526 adults with 
COPD and 4,030 individuals (including children and 
adults) with chronic liver disease associated with the 
PiZZ phenotype in Spain.(12) These data can serve 
as a reference to estimate, rather imprecisely, the 
impact of AAT deficiency in Brazil.
Molecular aspects
The glycoprotein AAT is encoded in the 
SERPINA1 gene, locus Pi, located on the long arm 
of chromosome 14 (14q31-32). It is a member 
of the superfamily of serine protease inhibitors, 
and its principal function is to inhibit a series of 
enzymes, among which are trypsin, elastase, and 
protease-3. Despite the nomenclature, AAT has a 
greater  inhibitory effect on neutrophil elastase than 
on trypsin.(6,13)
Introduction
Alpha-1 antitrypsin (AAT) deficiency is a genetic 
disease that has numerous clinical implications 
and primarily affects the lungs and liver. It is likely 
that the first case described was that of woman in 
Alaska approximately 800 years ago; it might also 
have contributed to the premature death of Frédéric 
Chopin in 1849.(1)
The first formal report of the disease occurred 
a little more than 40 years ago, when Laurell, 
while reviewing tests in his laboratory, noticed 
the absence of the alpha-1 band in electro-
phoreses of serum proteins from 5 patients.(2) 
Subsequent  investigations by Eriksson revealed that 
3 of those patients presented early emphysema, 
and another had a family history of pulmonary 
emphysema.(2) Thus, the disease and of some of its 
principal characteristics began to be recognized. 
Since then, significant advances and standardiza-
tion in the care of individuals with AAT deficiency 
have been described.(3,4) Novel diagnostic techniques 
have also been developed,(5) allowing the perform-
ance of large-scale epidemiological surveys—even 
allowing the genetic and pathophysiological bases 
of the disease to be studied.
Epidemiology
Epidemiological studies conducted world-
wide have shown that AAT deficiency is nearly as 
common as is cystic fibrosis, affecting one out of 
every 2,000-5,000 individuals.(6) Recent evidence 
obtained through genetic mapping indicates that 
the PiZ allele probably appeared in the north of 
Europe 107-135 generations (3,210-4,070 years) 
ago, in the Neolithic period, although it might have 
appeared as recently as 66 generations (approxi-
mately 2,000 years) ago.(7) Although the deficiency 
allele designated PiS would have appeared earlier, 
the data are less precise; it is estimated to have 
appeared 279-470 generations (8,370-14,100 years) 
ago, probably in the Iberian Peninsula, due to its 
high incidence in this region.(7) It is believed that 
at least one of those alleles is present in 70,000-
100,000 individuals in the United States, and that 
these figures are similar in Europe. It is estimated 
that the number of individuals with deficient vari-
ants is as high as 3.4 million.(8)
In the epidemiological study designated Proyecto 
Latinoamericano de Investigación en Obstrucción 
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the bronchial epithelium), and, through the circu-
lation, it reaches the lungs, where it will perform 
its anti-elastolytic function.(3) The circulating frac-
tion of AAT corresponds to approximately 40% of 
the total body levels of the protein; the remainder 
is found in the extravascular extracellular space, 
impregnating body tissues, such as the lungs, where 
it will take part in the tissue defense against elasto-
lysis. Serum levels of AAT can increase in situations 
of inflammation, and it is therefore considered an 
acute phase protein.(4)
The inhibition mechanism occurs when an AAT 
molecule binds to a protease molecule, in a system 
comparable to a mousetrap.(15) In this inhibition 
process, one AAT molecule is destroyed for each 
protease molecule inhibited, resulting in a net loss 
of AAT molecules. However, under normal condi-
tions, there is an excess of AAT in the lungs, which 
guarantees protection against the elastolytic effect 
of neutrophil elastase. In addition to acting as an 
antiprotease, AAT appears to serve an important 
anti-inflammatory function in the lungs.(16)
Pathophysiology
Polymerization
The substitution of lysine for glutamic acid at 
position 342 of the SERPINA1 gene configures 
protein Z.(6) The conformational changes originating 
from this mutation predispose the molecules to 
polymerization, which is irreversible, with conse-
It is known that AAT deficiency is a genetic 
disorder with autosomal codominant inheritance, 
and more than 100 alleles, approximately 30 of 
which can have clinical implications, have been 
identified to date.(14) The variants are designated by 
letters of the alphabet, according to the protease 
inhibitor system, based on molecule migration 
velocity in an isoelectric pH gradient.(13) Based on 
serum levels of AAT and molecular function, the 
variants are classified into four groups(3):
1) normal (normal serum AAT and normal func-
tion): M alleles
2) deficient (serum AAT less than one third of 
normal values): Z allele (the allele most often 
related to pulmonary disease), variant S, and 
rarer variants
3) null (undetectable serum level of AAT): QO 
alleles
4) dysfunctional (normal serum AAT but with 
reduced function): F and Pittsburgh alleles 
(among others)
Among all the variants related to clinical disease, 
mutation Z is the most common (approximately 
95% of the cases) and results from the substitution 
of lysine for glutamic acid at position 342 of the 
SERPINA1 gene.(13) Table 1 shows the most common 
variants, as well as the mutations and the related 
clinical data.
Physiology of AAT
The AAT molecule is produced mainly in the liver 
(and, in smaller quantities, in macrophages and in 
Table 1 - Some of the most common alleles related to alpha-1 antitrypsin deficiency, mutations involved, and related 
clinical data.(13) 
Alleles Type of mutation Associated disease(s)
Normal variants   
M (various subtypes) Substitution (1 base pair) None 
Deficient variants   
S Substitution (1 base pair) Pulmonary
Zª Substitution (1 base pair) Pulmonary, liver
Mmalton Deletion (3 base pairs) Pulmonary, liver
Siiyama Substitution (1 base pair) Pulmonary, liver
Null alleles   
QO (subtypes) Deletion or substitution Pulmonary, eventually liver
Dysfunctional alleles   
Pittsburgh Substitution (1 base pair) Hemorrhagic diathesis
Zª Substitution (1 base pair) Pulmonary, liver
ªThe Z allele is a deficiency allele, and it is also dysfunctional.
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tests commercially available) seem to be particu-
larly subject to the development of emphysema; at 
the same time, individuals with serum levels higher 
than that seem to be at a significantly lower risk 
of developing emphysema.(22) Therefore, the idea of 
a “protective threshold” (serum AAT ≥ 11 µmol/L) 
arose.(3,6)
Liver disease
Unlike pulmonary disease, AAT-deficiency-
related liver disease is not caused by the reduction 
in the serum levels of the enzyme, but by the accu-
mulation of polymers within hepatocytes. Therefore, 
only the individuals with mutations that result in 
polymerization, such as Siiyama, Mmalton, and, espe-
cially, Z, can present liver disease.(17) The mechanism 
through which intracellular accumulation of poly-
mers leads to liver injury, however, is still unknown.
After their formation, polymers accumulate in 
the endoplasmic reticulum of hepatocytes, where, 
under normal conditions, they are degraded by 
enzymes that function as “quality control” media-
tors. Liver disease, apparently, correlates with the 
result of the relationship between polymer forma-
tion and the capacity of the “quality control” cell 
system to degrade abnormally formed polymers.(23) 
There seems to be considerable individual variability 
in the degradation capacity of these polymers, 
which would explain why individuals with the same 
phenotype present varying degrees of liver disease.
Clinical manifestations
It has been shown that AAT deficiency is asso-
ciated with the development of pulmonary disease 
and liver disease, as well as with diseases in other 
quent accumulation of polymers within hepatocytes. 
Although this process can occur under normal condi-
tions, factors such as high concentrations of protein 
Z, high temperatures, and changes in pH facilitate 
polymerization.(17) As a consequence of polymer 
formation, only approximately 15% of the molecules 
produced reach the circulation, leading to a reduc-
tion in serum levels. In addition to protein Z, other 
mutations give rise to proteins subject to this polym-
erization process, such as Mmalton and others.
(18)
Pulmonary disease
When serum levels of AAT are low or some 
AAT molecules are dysfunctional, the lungs are not 
protected against the elastolytic effect of neutrophil 
elastase or against other injuries. Therefore, 
AAT-deficiency-related pulmonary emphysema 
has been attributed to protease-antiprotease imbal-
ance.(19) The resulting lesion would be a consequence 
of the increase in injury factors (smoking,  infections, 
and, occasionally, occupational factors) or of the 
decrease in protective mechanisms (notably, serum 
levels of AAT), with the balance being shifted in favor 
of the occurrence of accelerated lung injury.(6)
In addition to the quantitative changes, such as 
low tissue levels of AAT, the most common mutation 
(Z) makes the AAT molecule approximately five times 
less efficient in inhibiting neutrophil elastase(20) and 
subject to polymer formation, which contributes to 
lung injury.(21) Smoking, in addition to potentiating 
lung injury, reduces the activity of the AAT molecule 
as an antiprotease by approximately 2,000 times,(20) 
making it an important, avoidable factor for the 
development of emphysema.
Patients with serum levels of AAT lower than 
11 µmol/L (corresponding to 50-80 mg/dL in the 
Table 2 - Principal alpha-1 antitrypsin phenotypes, related serum levels, and associated risk of developing pulmonary 
or liver disease.(4)
Phenotype Serum level of alpha-1 antitrypsin Risk of emphysemaª Risk of liver diseaseª
mg/dL µmol/L
MM 103-200 20-39 No increase No increase
MS 100-180 19-35 No increase No increase
SS 70-105 14-20 No increase No increase
MZ 66-120 13-23 Possible slight increase Slight increase
SZ 45-80 9-15 Slight increase Slight increase
ZZ 10-40 2-8 High risk High risk
Null 0 0 High risk No increase
ªWhen compared with the normal population.
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Pulmonary disease caused by AAT deficiency is clini-
cally different from smoking-related COPD due to 
the fact that it has an earlier onset (fourth or fifth 
decade of life vs. sixth or seventh decade of life) and 
it is disproportionate to the tobacco intake.(6,24) At 
age 40, approximately 60% of nonsmokers with the 
PiZZ phenotype are symptomatic; ten years later, 
90% already present manifestations. In smokers, 
the symptoms appear even earlier, approximately 
ten years earlier.(4) Respiratory disease exacerba-
tions affect up to 50% of the patients, being more 
common in those with chronic bronchitis.(24)
The prevalence of bronchiectasis in individuals 
with AAT deficiency varies greatly. However, in the 
largest study sample to date, it was 26%, similar to 
what is observed in patients with COPD secondary 
to smoking.(27) When present, bronchiectasis is cylin-
drical or vesicular and is predominantly found in 
the lobes presenting the greatest degree of emphy-
sema, although, in exceptional cases, it can precede 
the development of emphysema. The mechanism 
for the development of bronchiectasis remains a 
matter of debate, and it has even been suggested 
that this condition results from changes in the 
lung parenchyma.(28) Despite the controversy, it is 
recommended that AAT levels be determined in the 
etiological investigation of cases of bronchiectasis 
without definite cause.(3)
It has been suggested that there is a relationship 
between AAT deficiency and asthma, although such 
organs and systems, although the last occur with 
less frequency. Nearly 80% of AAT-deficient patients 
are diagnosed on the basis of respiratory symptoms, 
compared with only 3% who are diagnosed on the 
basis of hepatic symptoms.(24) The recognition of 
AAT deficiency as the cause of pulmonary disease is 
important for the pulmonologist, since there can be 
a great delay between the onset of symptoms and 
diagnosis. In fact, in many patients, the recognition 
of mutations is achieved only very late and after 
appointments with different physicians; the interval 
between the onset of symptoms and the identifica-
tion of the disease can be eight or more years.(25)
The phenotype most often related to pulmonary 
manifestations (96% of the cases) is PiZZ, which 
implies serum AAT concentrations at less than 20% 
of the normal values.(4) However, heterozygous indi-
viduals with mutation Z (or rarer mutations) can 
also be at increased risk for emphysema, depending 
on multiple factors, such as smoking, occupational 
exposure, and environmental exposure (Table 2).
The usual clinical presentation is similar to 
that of smoking-related COPD. The most prevalent 
symptoms are dyspnea upon exertion (84% of the 
patients), respiratory-infection-related wheezing 
(76%), wheezing in the absence of infections (65%), 
expectoration (50%), and chronic cough (42%).(26) A 
profile consistent with chronic bronchitis (produc-
tive cough for three months in two  consecutive 
years) is seen in up to 40% of the patients.(3) 
Figure 1 - Routine anteroposterior and lateral chest X-ray of a patient with pulmonary emphysema secondary to 
alpha-1 antitrypsin deficiency. Note the signs of hyperinflation and hypertransparency of the lung parenchyma clearly 
predominant in the lung bases.
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possible association with AAT deficiency are, among 
others, panniculitis and vasculitis related to antineu-
trophil cytoplasmic antibodies.(24)
Radiological findings
On routine X-rays (Figure 1), AAT deficiency is 
characterized by signs of hyperinflation, such as 
lowering and rectification of the hemidiaphragm, 
an increase in the anteroposterior diameter of the 
chest, and an increase in the retrosternal air space. 
Findings of decreased bronchovascular markings and 
hypertransparent areas, predominantly in the lung 
bases, are also suggestive of the disease. However, 
these alterations can also be diffuse.(3)
High-resolution computed tomography (HRCT) 
of the chest (Figure 2) is a method that is more sensi-
tive for the detection of pulmonary disease than are 
routine X-rays, pulmonary function tests, or clinical 
profiles.(28) The characteristic pattern is panlobular 
a relationship has yet to be confirmed. In a study 
on the characteristics of asthma in patients listed in 
the North-American AAT Registry, 50% presented 
reversibility of airway obstruction in pulmonary 
function tests, and 22% met the criteria for the 
diagnosis of asthma (compared with 4.5% of the 
controls; p < 0.05).(29) Other studies, however, found 
no relationship between heterozygous pheno-
types and clinical or functional changes in asthma 
patients.(30)
There seem to be a relationship between occu-
pational exposure to particulate inhalants and the 
development of pulmonary disease in patients with 
the PiZZ phenotype.(31) An association between AAT 
deficiency and cancer, including lung cancer, has 
also been suggested.(32)
In relation to liver disease, AAT deficiency has 
been associated with neonatal cholestasis and early 
cirrhosis, which can evolve to hepatocellular carci-
noma.(18) Other manifestations described as having a 
Figure 2 - High resolution computed tomography scan of the chest of a patient with alpha-1 antitrypsin deficiency. 
Note that the emphysema, although diffuse, is predominant in the lung bases. There is also slight thickening of the 
bronchial walls and a small focus of ground-glass opacity in the posterior segment of the right lower lobe.
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augmentation therapy require evaluations that are 
more frequent and detailed.(4)
Natural history
It is estimated that up to 20% of individuals 
with the PiZZ phenotype do not develop emphy-
sema, even in autopsy studies.(6) Prior to the second 
decade of life, the most common manifestations 
are related to liver disease, and the development of 
pulmonary disease is rare.(33) One study found that 
the rate of FEV1 decline ranged from 41-109 mL/year 
in patients presenting clinical manifestations(34); this 
range, however, can be as large as 31-317 mL/year, 
depending on exposure to risk factors and on respi-
ratory symptoms.(4) The authors found the following 
to be risk factors for more rapid  progression: being 
a smoker; being male; being between 30 and 
44 years of age; presenting FEV1 between 35-79% 
of predicted; presenting bronchodilator responsive-
ness; and presenting low serum levels of AAT.(34)
Among the patients listed in the North-American 
AAT Registry, the 5-year mortality rate was 19%.(34) 
Respiratory insufficiency was the cause of death in 
72% of the cases, compared with approximately 
10% for liver cirrhosis. The risk factors for higher 
emphysema, which represents a simplification of 
the lung architecture, with decreased attenuation 
of the lung parenchyma on X-rays and decreased 
blood vessel number and diameter. Tomographic 
alterations are also classically described as being 
predominant in the lung bases, although it is impor-
tant to emphasize that, in up to 36% of the cases, 
they can extend to the lung apices and can occa-
sionally present apical predominance. Bullae are 
less common than in smoking-related emphysema. 
Bronchiectasis can also be present.(3,28)
The degree of impairment observed on chest 
HRCT scans presents a favorable correlation with 
anatomopathological and pulmonary function 
findings, and, therefore, HRCT has been proposed 
as a method for the follow-up evaluation of the 
progression of emphysema. However, this applica-
tion is limited by difficulties in the reproducibility 
of sequential tests, particularly those related to the 
intensity of inspiration, which directly influences 
the radiological density of the parenchyma.(28) At 
the moment, there is no formal recommendation 
regarding the need for tomographic follow-up eval-
uation of the disease, and the question of whether 
or not tomography is inedicated should be addressed 
on a case-by-case basis.(3)
Pulmonary function
The spirometric changes resulting from 
AAT-deficiency-related emphysema are the same 
described in smoking-related COPD: airflow obstruc-
tion, represented by a decrease in forced expiratory 
volume in one second/forced vital capacity (FEV1/
FVC) ratio and in FEV1; and normal or decreased 
FVC. Full pulmonary function testing reveals 
increased residual volume and greater total lung 
capacity, as well as decreased diffusing capacity of 
the lung for carbon monoxide. Due to air trapping, 
pulmonary volumes, as measured by plethysmog-
raphy, are typically greater than those measured 
by gas-dilution methods.(3) Some patients present 
significant variation in pulmonary function test 
results after bronchodilator use.(29)
The current recommendation is that, in the 
initial evaluation, full pulmonary function testing 
and arterial blood gas analysis be performed, and 
that, in the follow-up evaluation, simple spirometry 
be performed annually.(3) Patients treated with AAT 
Chart 1 - Clinical situations in which alpha-1 antitrypsin 
deficiency should be suspected and in which quantification 
of serum levels of alpha-1 antitrypsin is recommended.(3) 
Early emphysema (age < 45 years)
Emphysema in the absence of exposure to known risk 
factors (smoking, occupational factors)
Emphysema predominantly in the lung bases
Case of alpha-1 antitrypsin deficiency confirmed in the 
family
Family history of emphysema, dyspnea and cough; 
bronchiectasis, liver disease, or panniculitis
All individuals with chronic obstructive pulmonary 
disease
Asthma patients whose spirometry results do not 
normalize despite appropriate treatment
Adults with bronchiectasis without definite causeª
Liver disease without definite cause
Necrotic panniculitis
Vasculitis related to antineutrophil cytoplasmic 
antibodies
Absence of alpha-1 band confirmed by electrophoresis 
of serum proteins
ªConsider the determination of alpha-1 antitrypsin levels.
Alpha-1 antitrypsin deficiency: diagnosis and treatment
J Bras Pneumol. 2008;34(7):514-527
521
the local societies. Studies have demonstrated that 
phenotypic determination based on drops of blood 
on dry filter paper is feasible due to the fact that it 
is simple and affordable.(5)
The diagnosis of AAT, therefore, is confirmed 
when low serum levels are found concomitantly 
with a phenotype that is known to be related to 
the disease. Molecular-level diagnosis (genotyping), 
available in specialized laboratories, is an excep-
tional method for diagnostic confirmation in cases 
presenting discrepancies between the serum levels 
of AAT and the phenotype identified, being also 
recommended for the identification of rare variants 
and for the study of new variants.(4)
Treatment
Individuals with COPD secondary to AAT defi-
ciency should receive the standard treatment 
recommended in the principal guidelines currently 
available, including bronchodilators, inhaled 
corticosteroids (when indicated), and pulmonary 
rehabilitation, as well as early and appropriate treat-
ment of exacerbations.(38,39) In general, individuals 
with AAT deficiency present a normal immuno-
logical response, and vaccination is recommended 
(annually against influenza and every five years 
against pneumococci).(3) Smoking potentiates lung 
injury considerably, and smoking cessation should 
therefore be a fundamental objective of the treat-
ment.(4)
A possible exception to nonspecific treatment 
of the pulmonary disease is lung volume reduc-
tion surgery, which, in patients with AAT deficiency, 
has shown less favorable results.(40) The benefits of 
this surgery seem to be less significant and more 
 transitory. To date, there have been no recommen-
mortality were found to be advanced age, low level 
of education, low FEV1, having undergone lung 
 transplantation, and not receiving AAT  augmentation 
therapy. However, chest HRCT has proven to be the 
best predictor of mortality in patients with AAT 
deficiency, being even better than pulmonary func-
tion parameters.(35) Others factors that modify the 
natural history of AAT deficiency, including genetic 
and enzymatic polymorphisms, are gradually being 
identified.(36)
Diagnosis
The diagnosis of AAT deficiency involves the 
recognition of clinical patterns of the disease and 
the identification of the corresponding abnormal 
laboratory test results.(4) In patients with clinical 
changes suggestive of AAT deficiency—such as early 
emphysema, family history of emphysema, and liver 
disease without definite cause—the disease should 
be included in the differential diagnosis; in these 
clinical situations, as well as when the α1 band 
is faint or absent in the electrophoresis of serum 
proteins, serum levels of AAT should be quantified 
(Chart 1).(3)
The quantitative tests commercially available, 
which employ radial immunodiffusion or neph-
elometry, tend to overestimate serum levels when 
compared with the purified standard test by the 
National Heart, Lung, and Blood Institute.(37) In addi-
tion, AAT behaves as an acute phase protein, and its 
serum levels can be falsely increased during inflam-
matory and infectious processes.(4) Nevertheless, 
determining the serum levels of AAT is essential to 
the diagnostic process, although it must be borne 
in mind that normal values vary according to the 
method used (Table 3).(3)
Although different serum concentrations of AAT 
can suggest certain phenotypes, evidence of low or 
undetectable serum levels of AAT should prompt 
phenotypic study in order to identify AAT vari-
ants (based on the motility of the molecules in an 
isoelectric pH13 gradient) and confirm the diagnosis. 
Currently, in Brazil and in other countries, there are 
programs that offer simple methods for phenotypic 
determination through the collection of drops of 
blood with dry paper filter, which can be sent to a 
referral laboratory by mail. The materials required in 
order to perform these diagnostic methods can be 
easily obtained from the National Registry or from 
Table 3 - Methods available for determining serum levels 
of alpha-1 antitrypsin, as well as normal values and values 
considered “protective”.(3)
Method Normal ranges Protective 
threshold
Purified standard 
test (NHLBI)ª
20 to 53 µmol/L 11 µmol/L
Nephelometry 83-120 to 
200-220 mg/dL
50 mg/dL
Radial 
immunodiffusion
150-200 to 
350-400 mg/dL
80 mg/dL
ªNHLBI: National Heart, Lung, and Blood Institute.
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infusions throughout the treatment period (from 
51 to 33%).(45) In order to obtain a more comfort-
able dose schedule, studies have evaluated the 
pharmacokinetic profile of doses administered at 
greater intervals. In addition to weekly regimens of 
50 or 60 mg/kg, regimens of 100 or 120 mg/kg 
every 14 days, regimens of 150 or 180 mg/kg every 
21 days, and regimens of 250 mg/kg every 28 days 
have been tested.(46) Infusions of 50 or 60 mg/kg 
every 7 days and infusions of 100 or 120 mg/kg 
every 14 days maintained serum levels above the 
“protective threshold” in more than 85% of the 
interval between the doses (reaching 100% in the 
weekly regimen), and were considered appropriate. 
However, in order to achieve efficient serum levels 
(greater than 50 mg/dL) in the regimens with inter-
vals of 21 and 28 days, higher doses of AAT would be 
necessary, which, in practice, would increase treat-
ment costs. In a study conducted in Denmark,(47) 
the monthly infusion of 250 mg/kg resulted in 
insufficient serum levels on approximately 5 of the 
28 days of each cycle.
There have been few studies on the clinical 
efficacy of AAT augmentation therapy, revealing 
the methodological difficulties involved (size of 
the sample necessary and, principally, cost).(3) In 
the first study published on this subject (in 1997), 
the authors(48) found that the FEV1 decline was 
slower in patients who received AAT augmenta-
tion therapy than in those who did not (53 mL/year 
dations for lung volume reduction in this group of 
patients.(3)
Lung transplantation is another surgical option 
for patients with advanced pulmonary disease. 
Patients with AAT deficiency represent approxi-
mately 12% of all transplant recipients, with good 
functional results and mean five-year survival of 
approximately 50%.(41)
Alternative treatment of AAT deficiency
The specific treatment currently available for 
pulmonary disease secondary to AAT deficiency 
consists of periodic intravenous infusion of puri-
fied AAT from human plasma; such augmentation 
aims to raise the serum levels of AAT and, therefore, 
reconstitute the pulmonary defense against tissue 
elastolysis.(6)
Various formulations for clinical use, which differ 
as to the purification method used, are commercially 
available. Comparative studies have shown varying 
degrees of purity and in vitro activity.(42) However, 
the clinical implications of these differences have 
yet to be established.
Important points that should be considered 
regarding AAT augmentation therapy are efficacy 
in achieving certain outcomes (such as maintaining 
sufficient serum levels, delaying the decline in 
pulmonary function, and improving survival), safety, 
and cost-effectiveness.
Efficacy
The infusion of various AAT mixtures seems to 
meet the biochemical criteria of efficacy, and the 
anti-elastolytic activity of the molecules is main-
tained after intravenous administration.(43) In 
addition, it is possible to produce serum levels above 
the “protective threshold”, which is considered a 
fundamental point of AAT augmentation therapy.(3) 
In 1987, one group of authors(44) obtained, through 
weekly infusion of 60 mg/kg of AAT, serum levels 
typically higher than 11 µmol/L (or 50 mg/dL, 
through nephelometry), considered the target level 
for effective protection of the lung parenchyma.
Weekly administration, however, can become 
troublesome for patients, especially since they 
might need to stay in the hospital for up to 4 h, 
from the preparation of the medication to the end 
of the infusion. An observational study revealed a 
decrease in the proportion of patients using weekly 
Chart 2 - Minimum criteria necessary for recommending 
alpha-1 antitrypsin augmentation therapy according 
to the Spanish Society of Pulmonology and Thoracic 
Surgery.(4)
Age ≥ 18 years
Alpha-1 antitrypsin deficiency confirmed by serum levels 
≤ 35% of the normal values
PiZZ phenotype or rare deficient variants
Abstinence from smoking for at least six months
Pulmonary emphysema confirmed by clinical profile 
accompanied by FEV1/FVC < 0.70 and FEV1 < 80%
Confirmation of accelerated loss of pulmonary function 
in non-index casesª
Exclusion of associated immunoglobulin A deficiency
Patient’s commitment to the treatment
FEV1: forced expiratory volume in one second; and FVC: 
forced vital capacity. ªCases identified after investigation 
of the family history or screening.
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In addition to slowing the progression of 
emphysema, AAT augmentation therapy seems to 
have other beneficial effects, such as reducing the 
markers of bronchial inflammation.(16)
Safety
It has been shown that AAT augmentation 
therapy is well-tolerated. Most of the infusion side 
effects, such as headache, dizziness, nausea, and 
dyspnea, are mild or moderate. In addition, the 
frequency with which such effects occur is very low. 
Among patients listed in the North-American AAT 
Registry, there were an estimated 0.033 adverse 
events per patient/month, or approximately 2 events 
for each patient every five years of treatment. No 
contamination with the hepatitis virus or HIV was 
found.(45)
Cost-effectiveness and current 
recommendations
To date, only the biochemical efficacy of AAT 
augmentation therapy has been clearly confirmed, 
whereas the effect on relevant biological markers of 
the development of emphysema or the efficacy of 
AAT augmentation therapy on clinical and functional 
variables, as well as on variables of the progres-
sion of the disease, are still speculative. One of the 
main objectives of the International AAT Registry 
(see below) is to allow the design of comprehensive 
studies in order to answer these questions. Despite 
these limitations, AAT  augmentation therapy has 
been approved in some countries, including Brazil. 
It is not surprising that the few studies available 
vs. 74.5 mL/year; p = 0.02). Patients with an FEV1 
of 31-65% of predicted seemed to gain particular 
benefit.
A large observational study,(34) based on the 
North-American AAT Registry, showed a signifi-
cant overall reduction in mortality among patients 
receiving AAT augmentation therapy. In the 
subgroup of patients with an FEV1 of 35-49%, the 
decline in mortality was even more evident (rela-
tive risk of 0.21 for mortality in relation to those 
who were not treated; p < 0.001), and the reduction 
in loss of pulmonary function with the use of the 
treatment reached statistical significance.
In a cross-sectional study,(49) published in 
2001 and involving the follow-up evaluation of 
96 patients, it was shown that, in patients receiving 
AAT augmentation therapy, there was a reduction 
of approximately 15 mL (p = 0.019) in the annual 
decline in FEV1, and, unlike in previous studies, this 
reduction was more evident in the patients with less 
intense obstruction (FEV1 > 65%). The patients with 
a more rapid loss of pulmonary function presented 
the most expressive response, whereas those with 
an FEV1 of 30-65% showed only a tendency toward 
a reduction.
There has been only one randomized controlled 
study on the efficacy of AAT infusion.(47) In that 
study, in which 56 patients were randomized 
to receive monthly infusions of AAT or placebo 
(albumin), the authors demonstrated no improve-
ment in pulmonary function parameters, finding 
only a tendency (p = 0.07) toward a reduction in 
the progression of emphysema on the tomography 
scans of the patients who received the medication.
Table 4 - Complementary tests and periodicity of performance recommended by the Spanish Society of Pulmonology 
and Thoracic Surgery for the follow-up evaluation of patients with alpha-1 antitrypsin deficiency receiving alpha-1 
antitrypsin augmentation therapy.(4) 
Test Periodicity
Spirometry with bronchodilator Every three months
Static lung volumes Annually
Diffusing capacity of the lung for carbon 
monoxide
Annually
Arterial blood gas analysis and exercise tests Dependent on the clinical profile and other test results
Hepatic function Annually
Chest X-ray Every six months or when new symptoms appear
High resolution tomography of the chest In the initial evaluation; repeat only if justified by the clinical profile
Serologic testing for HIV and for hepatitis B and C Routine use not recommended, since there is no evidence of 
transmission of viral agents (with AAT augmentation therapy)
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good tolerability and maintenance of the elastolytic 
activity.(53) It is believed that one or two daily doses, 
which would be convenient, have a satisfactory 
anti-elastolytic effect.(3) However, the distribution of 
the molecules within the lungs seem to vary, being 
subject to the heterogeneity of the disease.(54) In 
cases of more severe obstruction, there is reduced 
peripheral deposition of particles, which could have 
clinical implications.
Studies evaluating the stimulation of endog-
enous production of AAT using danazol, taking 
advantage of the fact that the AAT molecule behaves 
as an acute phase reagent, have not demonstrated 
any clinical efficacy of such treatment. Similarly, 
therapies aimed at reducing lung injury (antioxi-
dants) or at promoting lung reepithelialization 
(all-trans-retinoic acid) have not provided benefits 
for patients.(14)
Therapies aimed at inhibiting polymerization, 
with reduced polymer accumulation in the liver 
and consequent increased serum levels of AAT, 
have been more promising. Researchers have been 
successfully developing specific peptides that bind 
with AAT molecules and cause in vitro inhibition of 
the polymerization process.(55)
Genetic therapies have also been the object of 
recent studies, involving the induction of normal 
AAT molecule production and the inhibition of 
mutant molecule production.(14) Normal genes have 
been successfully inserted, using viral vectors, into 
muscle and liver cells, as well as into the pleural 
space, resulting in sustained production of signif-
icant levels of AAT.(56) In a recent study,(57) which 
used clones of small interfering ribonucleic acid 
integrated into viral vectorsit was demonstrated 
that the production of AAT-Z was inhibited in 
mice. It was found that there was a reduction in the 
production and accumulation of molecules within 
hepatocytes three weeks later.
The international AAT registry
The Alpha One International Registry (AIR) was 
created in 1997, under the auspices of the World 
Health Organization, with the following objectives: 
to establish an international database including 
demographic description of the patients with AAT 
deficiency; to promote clinical and basic research 
for individuals with AAT deficiency and coordinate 
this activity; to collect, evaluate, and disseminate 
demonstrate that this is a therapy whose cost-
effectiveness is not highly favorable.(6,50) However, 
it is necessary to consider that AAT augmentation 
therapy is the only option of specific treatment 
available for such patients.
The benefits of AAT augmentation therapy seem 
to be more prominent in certain groups of patients, 
and international guidelines currently recommend 
that the use of AAT augmentation therapy be limited 
to patients with clinically established pulmonary 
disease that progresses despite optimal conven-
tional therapy.(3,4) Patients with moderate airflow 
obstruction (FEV1 of 35-60% of predicted) seem to 
gain more benefit from AAT augmentation therapy. 
However, it should be borne in mind that there is 
no consensus on whether or not AAT augmenta-
tion therapy is indicated; the authors of the British 
guidelines on COPD consider that, to date, there is 
insufficient evidence, and, therefore, they do not 
recommend AAT augmentation therapy.(51)
It has also been suggested that AAT augmen-
tation therapy in indicated for individuals with 
AAT deficiency submitted to lung transplantation. 
During episodes of rejection or infection, in view of 
the increased elastolytic activity, AAT augmentation 
therapy can be considered.(3,52)
Chart 2 shows the minimum criteria recom-
mended by the Sociedad Española de Neumología 
y Cirurgia Torácica (SEPAR, Spanish Society of 
Pulmonology and Thoracic Surgery) for indicating 
AAT augmentation therapy, and Table 4 shows 
the follow-up evaluation suggested by SEPAR 
for individuals with AAT deficiency receiving AAT 
augmentation therapy.(4)
New treatment perspectives
The use of intravenous AAT augmentation 
therapy has been limited by factors such as high 
cost, lack of proven efficacy, and inconvenient 
administration. Therefore, other forms of adminis-
tration have been sought, as have therapies that do 
not involve exogenous AAT augmentation therapy, 
either by stimulating the endogenous production of 
the molecule or by using other drugs.(14)
Some studies suggest inhalation as an alter-
native form of AAT augmentation therapy, with 
greater ease of administration and reduction in the 
dose needed. The pulmonary deposition of aero-
solized AAT particles is considered efficacious, with 
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Z-type alpha 1-antitrypsin is less competent than M1-type 
information about all aspects of the disease; to 
provide support and increase lay knowledge about 
AAT deficiency; and to stimulate the prevention of 
the progression of the disease and its treatment.(58) 
Therefore, a database with the best standardization 
possible was created. Since its creation, the AIR has 
had member countries on various continents and 
has been growing every year. In Brazil, AIR activities 
began in 2005, under the auspices of the Brazilian 
Thoracic Society and with the technical and scientific 
support of the Spanish Registry of AAT Deficiency, 
which is linked to SEPAR.
Patients presenting AAT levels below the normal 
values (preferably confirmed by nephelometry) 
should be listed in the Brazilian section of the 
registry, after confirmation of the presence of a 
phenotype related to AAT deficiency. The Brazilian 
section of the registry provides diagnostic kits for 
phenotype determination, upon request by the 
physician.
Final considerations
To date, only the biochemical efficacy of AAT 
augmentation therapy has been adequately evalu-
ated, and there are still no conclusive data regarding 
its clinical efficacy parameters or regarding biomar-
kers related to the development of pulmonary 
emphysema. The low prevalence of AAT deficiency, 
together with the general lack of cooperation 
from physicians regarding the international AAT 
registries, has made it impossible to develop new 
therapeutic alternatives more rapidly. With the crea-
tion and development of national and international 
AAT registries, this unfavorable scenario can be 
changed.
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